About rivastigmine hydrogen tartrate
Cholinesterase inhibitor
Used for
- Treats mild to moderate dementia due to Alzheimer’s disease
- Treats mild to moderate dementia associated with Parkinson’s disease
Usual adult dose
Usually starts at 1.5 mg twice daily with meals; increased gradually. Typical maintenance is 3–6 mg twice daily.
Common side effects
- Nausea, vomiting, diarrhea, or reduced appetite
- Weight loss
- Dizziness or fainting
- Slow heartbeat
Important warnings
- Dose increases should be gradual and supervised by a clinician.
- Risk of stomach bleeding, especially with ulcers or anti-inflammatory medicines.
- May worsen asthma, seizures, or urinary problems.
- Stopping for several days may require restarting at a lower dose.
Pregnancy
Human pregnancy information is limited; use only when a clinician determines it is necessary.
Breastfeeding
It is not known whether rivastigmine passes into breast milk; breastfeeding use requires clinical review.
Interactions
- Other cholinesterase inhibitors may increase side effects.
- Anticholinergic medicines may reduce its effects.
- Beta-blockers can increase the risk of a slow heartbeat or fainting.
- Metoclopramide may increase movement-related side effects.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.